Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4395089 · 1 trial · 1 indication
The percentage of participants who achieve endoscopic response at week 12 of Study Period 1.
| Arm | Type | Description |
|---|---|---|
| Mirikizumab | ACTIVE_COMPARATOR | Study Period 1: Mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC. |
| LY4395089 and Mirikizumab Co-Administration | EXPERIMENTAL | Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV. Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC. |
| Name | Type | Description |
|---|---|---|
| LY4395089 | DRUG | Administered orally |
| Mirikizumab - Intravenous (IV) | DRUG | Administered IV |
| Mirikizumab - Subcutaneous (SC) | DRUG | Administered SC |
Inclusion Criteria: Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below: * Participants taking glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), GLP-1/glucose-dependent insulinotropic ...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
LY4395089 is an investigational small molecule being studied for the treatment of Crohn disease, a chronic inflammatory bowel condition. It is in Phase 2 clinical development and is being evaluated in adults with Crohn disease. Eli Lilly and Company is developing the drug, and it is not yet approved for any indication.
LY4395089 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is the sponsor of the Phase 2 clinical program evaluating the drug in Crohn disease.
LY4395089 is in Phase 2 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is currently recruiting participants.
LY4395089 is being studied in one Phase 2 clinical trial, NCT07483099, titled A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease. The trial is recruiting and plans to enroll 60 adults across the United States, Belgium, Brazil, Canada, China, Germany, Hungary, Israel, Italy, and Poland.
Yes. The Phase 2 trial NCT07483099 evaluates LY4395089 given together with mirikizumab (LY3074828) and mirikizumab alone in adults with Crohn disease. The study is active-controlled, randomized, and recruiting, with an estimated enrollment of 60 participants.